Developer docs
API playgroundTry for free, no card

Search company profiles

Noucor

Full company profile

uuid000ab5y

Namestring
Noucor
Legal namestring
NOUCOR GROUP, S.L.
Websiteurl
noucor.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Noucor is a privately-held B2B pharmaceutical company headquartered in Palau-solità i Plegamans near Barcelona, Spain. It was incorporated in 2021 as the platform vehicle of MCH Private Equity and a group of Family Office investors, consolidating Urquima (fine chemicals / API manufacturing), Noucor Health (finished dose forms and food supplements) and adjacent subsidiaries into NOUCOR GROUP, S.L. The company employs more than 500 people across three production centers and sells exclusively through business-to-business channels—strategic licensing, direct API/FDF supply and CDMO services—to pharmaceutical counterparties in more than 100 markets worldwide. Its commercial portfolio spans three granted New Chemical Entities (Rupatadine, Flutrimazole, Triflusal), a pipeline of three additional NCEs available for licensing (Albaconazole in Phase IIb, UR-63325 and UR-65318 in earlier development), and a broad generic portfolio covering CNS, cardiology, respiratory and urology therapeutic areas.

Noucor's revenue model is built on four B2B streams: licensing and royalties on NCEs and Value-Added Medicines, transactional supply of generic APIs, one-time licensing-style supply of finished dose forms, and professional services for contract manufacturing of oral solids, semi-solids and food supplements. Pricing is not publicly disclosed and is set through long-term strategic agreements, co-development contracts and supply deals rather than list pricing. The go-to-market motion is sales-led with channel-partner overlays: APIs are commercialized worldwide through agreements with other pharmaceutical companies, while NCEs and differentiated generics are out-licensed to partners with regional commercial reach. Customer segmentation is vertical, focused on pharmaceutical companies requiring APIs, FDFs or CDMO capacity and on distributors, pharmacies and hospitals receiving the manufactured products through those channels.

The underlying technology is a vertically integrated chemical-pharmaceutical manufacturing platform rather than a software platform. Urquima operates a 12,800 m² multi-product chemical plant with kilolab, pilot, semi-industrial and industrial units, 56 tonnes/year API capacity and 130 m³ maximum reaction volume. Noucor Health operates a 63,000 m² site with 20,000 m² of production space capable of producing 1.8 billion tablets, 650 million film-coated tablets, 470 million capsules and 200 million food supplement units annually. The platform is held together by multi-jurisdictional GMP certifications (US FDA, Japan PMDA, Korea FDA, Spain AEMPS), ISO 13485, ISO 14001, ISO 45001 and ISO 22716 compliance, an EcoVadis Silver Medal (76/100, top 15% globally in 2025) and a patent estate covering both granted NCEs and filed/pending applications on Bilastine, Apremilast, Zonisamide, Silodosin, Ivabradine, Desvenlafaxine and Pirvinium pamoate. AI/ML and software capabilities are not present in the disclosed operating model.

Short descriptiontext

Noucor is a privately-held, B2B pharmaceutical company headquartered near Barcelona, Spain, operating vertically integrated manufacturing of generic APIs, finished dose forms, food supplements and licensed NCEs. It serves pharmaceutical counterparties in 100+ markets via licensing, supply contracts and CDMO services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, active pharmaceutical ingredients, finished dose forms, contract manufacturing services, generic medicines
Industry2 codes
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing of Innovative Products (NCEs)
TypeLicensing Royalties
Description

Long-term collaborations under strategic agreements for co-development, early/late licensing and distribution of New Chemical Entities. Products available for licensing include Albaconazole, UR-63325, UR-65318 in various development phases.

noucor.com
2Generic APIs Supply
TypeTransaction Fee
Description

Development and worldwide commercialization of Active Pharmaceutical Ingredients through agreements with other pharmaceutical companies. APIs manufactured at Urquima chemical plant under GMP standards.

noucor.com
3Finished Dose Forms (FDFs)
TypeOne Time License
Description

Development and supply of generic pharmaceutical products including tablets, film-coated tablets, capsules for CNS, cardiology, respiratory and urology therapeutic areas.

noucor.com
4Contract Manufacturing
TypeProfessional Services
Description

Development and manufacturing services for oral solids (tablets, film-coated tablets, capsules) and semi-solids (ointments, creams, gels) for other pharmaceutical companies. Also includes food supplements manufacturing.

noucor.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Operations, Personnel, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Noucor is a vertically integrated pharmaceutical company that develops, manufactures, and licenses active pharmaceutical ingredients (APIs), finished dose forms (FDFs), and proprietary new chemical entities (NCEs) for sale and out-licensing to B2B pharmaceutical customers across more than 50 countries. The company operates two manufacturing centers in the Barcelona area—Urquima for chemical/API production and Noucor Health for finished dosage forms—and offers contract manufacturing services for pharmaceutical and food supplement products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Present in 100+ markets worldwide
+3 more records
Product overview1 text field

Noucor is a vertically integrated B2B pharmaceutical company offering a diversified portfolio of innovative medicines (New Chemical Entities) and generic pharmaceutical products. The core offering includes three main commercial molecules (Rupatadine, Flutrimazole, Triflusal) alongside a pipeline of early-stage NCEs (Albaconazole, UR-63325, UR-65318). The company operates two manufacturing divisions: Urquima (chemical plant producing APIs with 56 tonnes/year capacity) and Noucor Health (pharmaceutical plant producing finished dose forms with 1.8B tablets/year capacity). Noucor also offers contract manufacturing services for oral solids and semi-solids, and maintains a separate food supplements manufacturing operation. All products are manufactured in-house from R&D through commercialization, with strategic therapeutic areas in Respiratory, Dermatology, CNS, Cardiology, and Urology.

Product and service1 record
1Generic Active Pharmaceutical Ingredients (APIs)
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

Noucor participates in ACCIÓ's International e-Trade Program, an initiative supporting international trade and business development for Catalan companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish-headquartered B2B pharmaceutical group with API manufacturing, CDMO services and licensing operations. Closest direct geographic and structural peer to Noucor, operating similar APIs, intermediates, and finished dose models from Spain.

2Chemo Group
TypeDirect peer
Description

Spanish-headquartered pharmaceutical group spanning API manufacturing, finished dose forms, and licensing across 100+ countries. Closely comparable to Noucor in geographic footprint, vertically integrated CDMO model, and B2B licensing strategy.

TypeDirect peer
Description

Swiss privately-held pharma group focused on oncology and supportive care, with licensing, manufacturing, and global commercial partnerships. Comparable to Noucor's NCE out-licensing model and B2B distribution focus, though focused on specialty therapeutics rather than generics.

TypeBroad incumbent
Description

API division of Teva Pharmaceutical Industries, one of the world's largest generic API manufacturers. Comparable to Noucor on generic API portfolio breadth and global supply footprint, though materially larger and integrated with Teva's finished-dose operations.

TypeDirect peer
Description

Vertically integrated global generic API and finished dosage form manufacturer with strong US/EU regulatory footprint. Directly comparable to Noucor on API-to-FDF vertical integration, generic molecule portfolio breadth, and B2B commercial model.

TypeDirect peer
Description

Spanish fine chemicals and API manufacturer serving global pharmaceutical companies. Closely comparable to Noucor's Urquima division on chemical synthesis capabilities, GMP compliance, and B2B API supply model.

TypeEmerging player
Description

Global CDMO providing API development, manufacturing and finished dose services to pharma partners. Comparable to Noucor on contract manufacturing services and API capabilities, with overlap in oral solid dose expertise.

TypeDirect peer
Description

Indian-headquartered vertically integrated pharma with API manufacturing, generic FDFs, and proprietary product licensing. Comparable to Noucor across API-to-FDF model, regulated-market certifications, and emerging pipeline out-licensing strategy.

9Medichem
TypeDirect peer
Description

Spanish API manufacturer and CDMO with deep expertise in generic active ingredients for global pharma partners. Comparable to Noucor's Urquima API business on technology platform, customer type, and geographic reach in regulated markets.

TypeBroad incumbent
Description

Larger Spanish private pharmaceutical company with proprietary specialty products, generics, API manufacturing, and CDMO capabilities. Comparable end-to-end pharma model but with broader branded portfolio and global commercial reach beyond Noucor's current scope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Noucor

Pharmaceutical Manufacturingnoucor.com

Noucor is a privately-held, B2B pharmaceutical company headquartered near Barcelona, Spain, operating vertically integrated manufacturing of generic APIs, finished dose forms, food supplements and licensed NCEs. It serves pharmaceutical counterparties in 100+ markets via licensing, supply contracts and CDMO services.

What Noucor does

Noucor is a privately-held B2B pharmaceutical company headquartered in Palau-solità i Plegamans near Barcelona, Spain. It was incorporated in 2021 as the platform vehicle of MCH Private Equity and a group of Family Office investors, consolidating Urquima (fine chemicals / API manufacturing), Noucor Health (finished dose forms and food supplements) and adjacent subsidiaries into NOUCOR GROUP, S.L. The company employs more than 500 people across three production centers and sells exclusively through business-to-business channels—strategic licensing, direct API/FDF supply and CDMO services—to pharmaceutical counterparties in more than 100 markets worldwide. Its commercial portfolio spans three granted New Chemical Entities (Rupatadine, Flutrimazole, Triflusal), a pipeline of three additional NCEs available for licensing (Albaconazole in Phase IIb, UR-63325 and UR-65318 in earlier development), and a broad generic portfolio covering CNS, cardiology, respiratory and urology therapeutic areas.

Noucor's revenue model is built on four B2B streams: licensing and royalties on NCEs and Value-Added Medicines, transactional supply of generic APIs, one-time licensing-style supply of finished dose forms, and professional services for contract manufacturing of oral solids, semi-solids and food supplements. Pricing is not publicly disclosed and is set through long-term strategic agreements, co-development contracts and supply deals rather than list pricing. The go-to-market motion is sales-led with channel-partner overlays: APIs are commercialized worldwide through agreements with other pharmaceutical companies, while NCEs and differentiated generics are out-licensed to partners with regional commercial reach. Customer segmentation is vertical, focused on pharmaceutical companies requiring APIs, FDFs or CDMO capacity and on distributors, pharmacies and hospitals receiving the manufactured products through those channels.

The underlying technology is a vertically integrated chemical-pharmaceutical manufacturing platform rather than a software platform. Urquima operates a 12,800 m² multi-product chemical plant with kilolab, pilot, semi-industrial and industrial units, 56 tonnes/year API capacity and 130 m³ maximum reaction volume. Noucor Health operates a 63,000 m² site with 20,000 m² of production space capable of producing 1.8 billion tablets, 650 million film-coated tablets, 470 million capsules and 200 million food supplement units annually. The platform is held together by multi-jurisdictional GMP certifications (US FDA, Japan PMDA, Korea FDA, Spain AEMPS), ISO 13485, ISO 14001, ISO 45001 and ISO 22716 compliance, an EcoVadis Silver Medal (76/100, top 15% globally in 2025) and a patent estate covering both granted NCEs and filed/pending applications on Bilastine, Apremilast, Zonisamide, Silodosin, Ivabradine, Desvenlafaxine and Pirvinium pamoate. AI/ML and software capabilities are not present in the disclosed operating model.

Noucor firmographics

Firmographics
Name
Noucor
Legal name
NOUCOR GROUP, S.L.
Website
https://noucor.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
251–500 employees
Short description
Noucor is a privately-held, B2B pharmaceutical company headquartered near Barcelona, Spain, operating vertically integrated manufacturing of generic APIs, finished dose forms, food supplements and licensed NCEs. It serves pharmaceutical counterparties in 100+ markets via licensing, supply contracts and CDMO services.
Ownership category
akta.pro rank

Noucor industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • Finished dose forms
  • Contract manufacturing services
  • Generic medicines

Where Noucor is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Noucor business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain

Revenue model

  1. Licensing of Innovative Products (NCEs): Long-term collaborations under strategic agreements for co-development, early/late licensing and distribution of New Chemical Entities. Products available for licensing include Albaconazole, UR-63325, UR-65318 in various development phases.
  2. Generic APIs Supply: Development and worldwide commercialization of Active Pharmaceutical Ingredients through agreements with other pharmaceutical companies. APIs manufactured at Urquima chemical plant under GMP standards.
  3. Finished Dose Forms (FDFs): Development and supply of generic pharmaceutical products including tablets, film-coated tablets, capsules for CNS, cardiology, respiratory and urology therapeutic areas.
  4. Contract Manufacturing: Development and manufacturing services for oral solids (tablets, film-coated tablets, capsules) and semi-solids (ointments, creams, gels) for other pharmaceutical companies. Also includes food supplements manufacturing.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Noucor product offering

Product offering

Core offering

Noucor is a vertically integrated pharmaceutical company that develops, manufactures, and licenses active pharmaceutical ingredients (APIs), finished dose forms (FDFs), and proprietary new chemical entities (NCEs) for sale and out-licensing to B2B pharmaceutical customers across more than 50 countries. The company operates two manufacturing centers in the Barcelona area—Urquima for chemical/API production and Noucor Health for finished dosage forms—and offers contract manufacturing services for pharmaceutical and food supplement products.

Product overview

Noucor is a vertically integrated B2B pharmaceutical company offering a diversified portfolio of innovative medicines (New Chemical Entities) and generic pharmaceutical products. The core offering includes three main commercial molecules (Rupatadine, Flutrimazole, Triflusal) alongside a pipeline of early-stage NCEs (Albaconazole, UR-63325, UR-65318). The company operates two manufacturing divisions: Urquima (chemical plant producing APIs with 56 tonnes/year capacity) and Noucor Health (pharmaceutical plant producing finished dose forms with 1.8B tablets/year capacity). Noucor also offers contract manufacturing services for oral solids and semi-solids, and maintains a separate food supplements manufacturing operation. All products are manufactured in-house from R&D through commercialization, with strategic therapeutic areas in Respiratory, Dermatology, CNS, Cardiology, and Urology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic Active Pharmaceutical Ingredients (APIs)

Quantifiable outcome

  • Present in 100+ markets worldwide
  • +3 more outcomes

Companies that use Noucor

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Noucor technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Noucor partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ACCIÓ International e-Trade ProgramminorOthersNoucor participates in ACCIÓ's International e-Trade Program, an initiative supporting international trade and business development for Catalan companies.

Scale indicators15 records

Recent moves7 records

Expansion highlights5 records

Noucor competitors and assessment

Company assessment

Direct peers

  • Suanfarma: Spanish-headquartered B2B pharmaceutical group with API manufacturing, CDMO services and licensing operations. Closest direct geographic and structural peer to Noucor, operating similar APIs, intermediates, and finished dose models from Spain.
  • Chemo Group: Spanish-headquartered pharmaceutical group spanning API manufacturing, finished dose forms, and licensing across 100+ countries. Closely comparable to Noucor in geographic footprint, vertically integrated CDMO model, and B2B licensing strategy.
  • Helsinn Group: Swiss privately-held pharma group focused on oncology and supportive care, with licensing, manufacturing, and global commercial partnerships. Comparable to Noucor's NCE out-licensing model and B2B distribution focus, though focused on specialty therapeutics rather than generics.
  • Aurobindo Pharma: Vertically integrated global generic API and finished dosage form manufacturer with strong US/EU regulatory footprint. Directly comparable to Noucor on API-to-FDF vertical integration, generic molecule portfolio breadth, and B2B commercial model.
  • Farmhispania: Spanish fine chemicals and API manufacturer serving global pharmaceutical companies. Closely comparable to Noucor's Urquima division on chemical synthesis capabilities, GMP compliance, and B2B API supply model.
  • Dr. Reddy's Laboratories: Indian-headquartered vertically integrated pharma with API manufacturing, generic FDFs, and proprietary product licensing. Comparable to Noucor across API-to-FDF model, regulated-market certifications, and emerging pipeline out-licensing strategy.
  • Medichem: Spanish API manufacturer and CDMO with deep expertise in generic active ingredients for global pharma partners. Comparable to Noucor's Urquima API business on technology platform, customer type, and geographic reach in regulated markets.

Broad incumbents

  • Teva API: API division of Teva Pharmaceutical Industries, one of the world's largest generic API manufacturers. Comparable to Noucor on generic API portfolio breadth and global supply footprint, though materially larger and integrated with Teva's finished-dose operations.
  • Esteve Pharmaceuticals: Larger Spanish private pharmaceutical company with proprietary specialty products, generics, API manufacturing, and CDMO capabilities. Comparable end-to-end pharma model but with broader branded portfolio and global commercial reach beyond Noucor's current scope.

Emerging players

  • Curia (formerly AMRI): Global CDMO providing API development, manufacturing and finished dose services to pharma partners. Comparable to Noucor on contract manufacturing services and API capabilities, with overlap in oral solid dose expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Noucor social profiles

Digital presence

Noucor compliance and trust

Trust signal

Compliance6 records

Noucor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Noucor leadership team

Management profile

Number of profiles

Profiles1 record

Noucor subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Noucor funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Noucor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noucor

What does Noucor do?

Noucor is a vertically integrated pharmaceutical company that develops, manufactures, and licenses active pharmaceutical ingredients (APIs), finished dose forms (FDFs), and proprietary new chemical entities (NCEs) for sale and out-licensing to B2B pharmaceutical customers across more than 50 countries. The company operates two manufacturing centers in the Barcelona area—Urquima for chemical/API production and Noucor Health for finished dosage forms—and offers contract manufacturing services for pharmaceutical and food supplement products.

Is Noucor a public or private company?

Noucor is a private company. It is classified as private equity controlled and is currently operating.

When was Noucor founded?

Noucor was founded in 2021. It employs 251 to 500 people.

Where is Noucor based?

Noucor is headquartered in Barcelona, Spain, in the Europe region.

How does Noucor make money?

Four revenue lines are on record. Licensing of Innovative Products (NCEs) is the primary driver. The others are generic APIs Supply, finished Dose Forms (FDFs) and contract Manufacturing.

Who are Noucor's main competitors?

Direct peers on record are Suanfarma, Chemo Group, Helsinn Group, Aurobindo Pharma, Farmhispania, Dr. Reddy's Laboratories and Medichem. Broad incumbents are Teva API and Esteve Pharmaceuticals. Curia (formerly AMRI) is listed as an emerging player.

Does Noucor have an API?

No public API is recorded for Noucor.

What industry is Noucor in?

Noucor's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals